6/21/2026

Janusmed sex and gender

Janusmed sex and gender – Cenobamate

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Cenobamate

Cenobamate

Class : A

Show all info

Print

Contact us

  1. Christian CA, Reddy DS, Maguire J, Forcelli PA. Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies. Pharmacol Rev. 2020;72(4):767-800.

  2. Reddy DS, Thompson W, Calderara G . Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett. 2021;750:135753.

  3. McHugh JC, Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol. 2008;83:11-26.

  4. Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007;76(1):60-5.

  5. Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia. 2005;46(6):956-60.

  6. Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2005;39(3):956-60.

  7. Ontozry (cenobamate). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-04-23, cited 2026-03-24]

  8. Food and Drug Administration (FDA). Prescribing information - XCOPRI (cenobamate). DailyMed [www]. [cited 2026-03-24].

  9. Operto FF, Izzo V, Assenza G, et al. Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study. Front Pharmacol. 2025;16:1668382.

  10. Charlier B, Izzo V, Assenza G, et al. Do Cenobamate Pharmacokinetics Change with Co-Administered Antiseizure Medications? An Exploratory Analysis of Responder Patients with Focal Drug-Resistant Epilepsy. Pharmaceutics. 2026;18(1):92.

  11. Food and Drug Administration (FDA). Statistical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2018-02-15, cited 2026-03-24].

  12. Czapińska-Ciepiela E, Kondak A, Kowalczyk M, et al. Early antiseizure response to cenobamate (200 mg/day) in focal drug-resistant epilepsy: a retrospective single-center analysis. Epilepsy Behav Rep. 2025;32:100839.

  13. Strzelczyk A, von Podewils F, Hamer HM, et al. Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study. CNS Drugs. 2025;39(3):321-331.

  14. Winter Y, Dargham RA, Ellwardt E, et al. Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. Epilepsy Behav. 2026;175:110835.

  15. Food and Drug Administration (FDA). Clinical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2019-10-15, cited 2026-03-24].

  16. Iwamoto BK, Whitaker AM, Agurs LD, et al. Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations. J Child Neurol. 2026;41(3):336-344.

  17. Hashem J, Ade S, Ivanier S, et al. Cenobamate-associated weight loss (Cenobaweight study). Cenobamate-associated weight loss (Cenobaweight study). 2025.

  18. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Christian CA, Reddy DS, Maguire J, Forcelli PA. Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies. Pharmacol Rev. 2020;72(4):767-800.
  2. Reddy DS, Thompson W, Calderara G . Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett. 2021;750:135753.
  3. McHugh JC, Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol. 2008;83:11-26.
  4. Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007;76(1):60-5.
  5. Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia. 2005;46(6):956-60.
  6. Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2005;39(3):956-60.
  7. Ontozry (cenobamate). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-04-23, cited 2026-03-24]
  8. Food and Drug Administration (FDA). Prescribing information - XCOPRI (cenobamate). DailyMed [www]. [cited 2026-03-24].
  9. Operto FF, Izzo V, Assenza G, et al. Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study. Front Pharmacol. 2025;16:1668382.
  10. Charlier B, Izzo V, Assenza G, et al. Do Cenobamate Pharmacokinetics Change with Co-Administered Antiseizure Medications? An Exploratory Analysis of Responder Patients with Focal Drug-Resistant Epilepsy. Pharmaceutics. 2026;18(1):92.
  11. Food and Drug Administration (FDA). Statistical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2018-02-15, cited 2026-03-24].
  12. Czapińska-Ciepiela E, Kondak A, Kowalczyk M, et al. Early antiseizure response to cenobamate (200 mg/day) in focal drug-resistant epilepsy: a retrospective single-center analysis. Epilepsy Behav Rep. 2025;32:100839.
  13. Strzelczyk A, von Podewils F, Hamer HM, et al. Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study. CNS Drugs. 2025;39(3):321-331.
  14. Winter Y, Dargham RA, Ellwardt E, et al. Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. Epilepsy Behav. 2026;175:110835.
  15. Food and Drug Administration (FDA). Clinical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2019-10-15, cited 2026-03-24].
  16. Iwamoto BK, Whitaker AM, Agurs LD, et al. Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations. J Child Neurol. 2026;41(3):336-344.
  17. Hashem J, Ade S, Ivanier S, et al. Cenobamate-associated weight loss (Cenobaweight study). Cenobamate-associated weight loss (Cenobaweight study). 2025.
  18. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]